Bayer CropScience Limited

BSE:506285 株式レポート

時価総額：₹196.6b

Bayer CropScience マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Simon-Thorsten Wiebusch

最高経営責任者

₹87.5m

報酬総額

CEO給与比率82.06%
CEO在任期間2.5yrs
CEOの所有権n/a
経営陣の平均在職期間2.1yrs
取締役会の平均在任期間1.8yrs

経営陣の近況

Recent updates

ナラティブの更新 • May 01

506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook

Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.
ナラティブの更新 • Apr 17

506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook

The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.
ナラティブの更新 • Apr 02

506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook

Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.
ナラティブの更新 • Mar 19

506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook

Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).
ナラティブの更新 • Mar 04

506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook

Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).
ナラティブの更新 • Feb 17

506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook

Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).
ナラティブの更新 • Feb 03

506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year

Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.
ナラティブの更新 • Jan 20

506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year

Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.
ナラティブの更新 • Jan 05

506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year

Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.
ナラティブの更新 • Dec 21

506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year

Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.
ナラティブの更新 • Dec 07

506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025

Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.
ナラティブの更新 • Nov 23

506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025

Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.
User avatar
新しいナラティブ • May 18

Seeds, Traits And Biofuels Will Unlock New Value Pools

Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.

CEO報酬分析

Bayer CropScience の収益と比較して、Simon-Thorsten Wiebusch の報酬はどのように変化したか？
日付総報酬給与会社業績
Dec 31 2025n/an/a

₹7b

Sep 30 2025n/an/a

₹6b

Jun 30 2025n/an/a

₹6b

Mar 31 2025₹87m₹72m

₹6b

Dec 31 2024n/an/a

₹5b

Sep 30 2024n/an/a

₹6b

Jun 30 2024n/an/a

₹7b

Mar 31 2024₹86m₹70m

₹7b

Dec 31 2023n/an/a

₹8b

Sep 30 2023n/an/a

₹8b

Jun 30 2023n/an/a

₹8b

Mar 31 2023₹96m₹82m

₹8b

Dec 31 2022n/an/a

₹8b

Sep 30 2022n/an/a

₹7b

Jun 30 2022n/an/a

₹7b

Mar 31 2022₹29m₹25m

₹6b

報酬と市場: Simon-Thorstenの 総報酬 ($USD 918.44K ) は、 Indian市場 ($USD 475.51K ) の同規模の企業の平均を上回っています。

報酬と収益: Simon-Thorstenの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Simon-Thorsten Wiebusch (49 yo)

2.5yrs
在職期間
₹87,470,000
報酬

Mr. Simon-Thorsten Wiebusch is Vice Chairman, Managing Director and Chief Executive Officer of Bayer CropScience Limited from November 1, 2023. Mr. Wiebusch was Whole-Time Director at Bayer CropScience Lim...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Simon-Thorsten Wiebusch
Vice Chairman2.5yrs₹87.47mデータなし
Vinit Jindal
Whole-Time Executive Director & CFO1.2yrs₹3.74mデータなし
Bharati Shetty
Company Secretary & Compliance Officer1.8yrsデータなしデータなし
Shweta Rai
Country Division Head of the Pharmaceutical Division2.3yrsデータなしデータなし
Dinesh Bapat
Country Group Mngr of Environmental Science for Indiano data₹2.36mデータなし
2.1yrs
平均在職期間

経験豊富な経営陣: 506285の経営陣は 経験豊富 であると考えられます ( 2.1年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Simon-Thorsten Wiebusch
Vice Chairman4.4yrs₹87.47mデータなし
Vinit Jindal
Whole-Time Executive Director & CFO1.2yrs₹3.74mデータなし
Pankaj Patel
Non-Executive Independent Chairman9.8yrs₹2.06mデータなし
Radhika Rajan
Non-Executive Woman Independent Director1.8yrs₹660.00kデータなし
Sanjiv Rangrass
Additional Non-Executive Independent Directorless than a yearデータなしデータなし
Thomas Hoffmann
Non-Executive Non-Independent Director6.7yrsデータなしデータなし
Jana Ackermann
Non-Executive Non-Independent Director1.2yrsデータなしデータなし
1.8yrs
平均在職期間
65yo
平均年齢

経験豊富なボード: 506285の 取締役会 は 経験豊富 ではない ( 1.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/25 10:11
終値2026/05/25 00:00
収益2025/12/31
年間収益2025/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Bayer CropScience Limited 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26

アナリスト機関
null null360 ONE Capital Market Private Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Himanshu BinaniAnand Rathi Shares and Stock Brokers Limited